Alagille Syndrome Clinical Trials

36 clinical trials for Alagille Syndrome across international registries, including 8 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study to Observe the Long-term Safety of Odevixibat in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment — RECRUITING
• A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment — RECRUITING
• Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome or Progressive Familial Intrahepatic Cholestasis in the European Union (LEAP-EU) — RECRUITING · PHASE4
• Pediatric Evaluation and Registry for Liver Cholestasis in Canada — RECRUITING
• A Database Study of Maralixibat (TAK-625) in Participants With Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC) — RECRUITING
• Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford — RECRUITING
• Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US) — RECRUITING
• A MULTICENTER EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND DURABILITY OF THE THERAPEUTIC EFFECT OF LUM001, AN APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITOR (ASBTI), IN THE TREATMENT OF CHOLESTATIC LIVER DISEASE IN PEDIATRIC SUBJECTS WITH ALAGILLE SYNDROME — RECRUITING
• Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome — ACTIVE_NOT_RECRUITING · PHASE3
• An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients with Alagille Syndrome (ASSERT-EXT) — TERMINATED · PHASE3
• Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC) — SUSPENDED
• A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS). — COMPLETED · PHASE2
• Atorvastatin Therapy on Xanthoma in Alagille Syndrome — COMPLETED · PHASE4
• A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS) — COMPLETED · PHASE3
• FibroScan™ in Pediatric Cholestatic Liver Disease (FORCE) — COMPLETED
• An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects — COMPLETED · PHASE1
• A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384 — COMPLETED · PHASE1
• Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome — COMPLETED · PHASE3
• Decreasing Hemorrhage Risk in Children With Alagille Syndrome — OTHER · NA
• An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS) — COMPLETED · PHASE2
• A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome (ALGS) — OTHER
• AN OPEN LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF ODEVIXIBAT (A4250) IN PATIENTS WITH ALAGILLE SYNDROME — COMPLETED
• Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS) — COMPLETED · PHASE2
• An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome — COMPLETED · PHASE2
• A PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF ODEVIXIBAT (A4250) IN PATIENTS WITH ALAGILLE SYNDROME (ASSERT) — COMPLETED · PHASE3
• A LONG-TERM SAFETY STUDY OF MARALIXIBAT, AN APICAL SODIUM DEPENDENT BILE ACID TRANSPORTER INHIBITOR (ASBTI), IN THE TREATMENT OF CHOLESTATIC LIVER DISEASE IN SUBJECTS WHO PREVIOUSLY PARTICIPATED IN A MARALIXIBAT STUDY — COMPLETED
• Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome — COMPLETED · PHASE2
• Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome — COMPLETED · PHASE2
• Validation of the Itch Reported Outcome (ItchRO) Diaries in Pediatric Cholestatic Liver Disease — COMPLETED
• Characterization of Pulmonary Artery Stenoses in Alagille Syndrome - a Medical Record Review — COMPLETED
• ICONIC STUDY LONG-TERM, OPEN-LABEL STUDY WITH A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED DRUG WITHDRAWAL PERIOD OF LUM001, AN APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITOR (ASBTI), IN PATIENTS WITH ALAGILLE SYNDROME — COMPLETED
• A MULTICENTRE EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND DURABILITY OF THE THERAPEUTIC EFFECT OF LUM001, AN APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITOR (ASBTI), IN THE TREATMENT OF CHOLESTATIC LIVER DISEASE IN PEDIATRIC SUBJECTS WITH ALAGILLE SYNDROME — COMPLETED
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LUM001, AN APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITOR (ASBTI), IN THE TREATMENT OF CHOLESTATIC LIVER DISEASE IN PAEDIATRIC PATIENTS WITH ALAGILLE SYNDROME — COMPLETED
• THE EVALUATION OF THE INTESTINAL BILE ACID TRANSPORT (IBAT) INHIBITOR LUM001 IN THE REDUCTION OF PRURITUS IN ALAGILLE SYNDROME, A CHOLESTATIC LIVER DISEASE — COMPLETED
• Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease — COMPLETED · NA
• Positional Cloning of the Gene(s) Responsible for Alagille Syndrome — COMPLETED

Refine this search